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Just how difficult can it be counting up R&D
funding for emerging technologies (and is
tech mining with proxy measures going to be
any better)?
Michael M. Hopkins∗ and Josh Siepel
SPRU, Freeman Centre, University of Sussex, UK
Decision makers considering policy or strategy related to the development of emerging tech-
nologies expect high quality data on the support for different technological options in order to
track trends and allocate resources. A natural starting point would be R&D funding statistics.
This paper explores the limitations of such aggregated data in relation to the substance and
quantification of funding for emerging technologies. Using biotechnology as an illustrative
case, we test the utility of a novel taxonomy to demonstrate the endemic weaknesses in the
availability and quality of data from public and private sources. Using the same taxonomy, we
consider the extent to which tech-mining presents an alternative, or potentially complemen-
tary, way to determine support for emerging technologies using proxy measures such as patents
and scientific publications. We find that using proxy measures provides additional visibility of
technological emergence and suggest these are a useful complement to financial data.
Keywords: science and technology and innovation policy studies; technology and innovation
studies; science and technology indicators; emerging technologies; data mining; social shaping
of technology
1. Introduction
Emerging technologies, when combined with innovative entrepreneurs and complementary insti-
tutional changes, have the potential to generate super-profits and economic growth (Freeman and
Louçã 2001). Harnessing such technologies is a key objective for government policy makers
and industrialists alike, with the means to evaluate related activity and progress increasingly val-
ued (Martin 1996; Patel 2012). In the present economically challenging times, as funds invested
in R&D are restricted, the ability to make important decisions that will affect the viability of
particular technological options becomes even more important.
Yet decisions about the funding of technological options are not made in a vacuum, as emerg-
ing technologies are socially shaped and are selected over other potential options (Bijker 1995;
∗Corresponding author. Email: m.m.hopkins@sussex.ac.uk
© 2013 Taylor & Francis
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656 M.M. Hopkins and J. Siepel
Smith, Voß, and Grin 2010). The outcomes of this struggle often reflect the agendas of power-
ful actor groups with vested interests (Jacobsson and Johnson 2000; Verbong and Geels 2007).
The thinking of these groups, their norms and routines thus constrain scientific and technolog-
ical paradigms (Dosi 1982). For example, the emerging literature on ‘pharmaceuticalisation’
examines how heavy private investment in pharmaceutical R&D and marketing has led to an
assumed societal focus on pharmaceutical approaches to mitigating disease, at the expense of
non-pharmaceutical approaches that are either underutilised or ignored (Abraham 2010; Williams,
Martin, and Gabe 2011).
It follows that when policymakers, firms and academics review the funding of a range of distinct
technological options they will often be dependent upon information about these options derived
in a highly politicised context, with R&D funding data not being exempt from influence even if this
manifests as a lack of will to generate accurate data. The continued absence of suitably complete
data (i.e. spanning public and private sectors, national boundaries, different technological fields) in
economically important areas such as energy and bioscience has recently been noted in unrelated
fields (Anon 2010; House of Lords 2010). This is despite a notable emphasis in some countries such
as the USA and UK on developing systems to record investments and related impacts by public
sector and charitable research funders.1 In the absence of robust, complete and objective data on
funding, not only is there a lack of accountability but also the potential for loss of national capacity
and opportunities if clear figures for R&D investment are not available to policymakers. For
example, in 2010 a UK parliamentary Committee considering the prioritisation of national public
R&D spending found that ‘aggregated information on how much is spent on particular aspects of
research and development within key sectors was not readily available; as a result, it was difficult
to identify the reasons why resources were distributed as they were’ (para. 28).2 The problem is
not limited to the UK. When Texas state Senator Steve Ogden sought to ban stem cell research in
the state in 2009, a lack of data on funding stymied his attempts, as it was unclear how extensive
the impact of legislative change would be on Texan institutions (Matthews and Rowland 2011).
This paper addresses the following questions: (i) Why is relevant R&D funding data often in fact
misleading or unavailable? (ii) How best can data be obtained to inform decision making to support
the development of emerging technological options in science-intensive areas of technological
change?
In addressing these questions we note how this focus poses distinct methodological challenges
to those described in prior work on measuring innovative activity or research quality (previously
reviewed by Patel (2012) and Martin (1996)).
Regarding the first question, we explore the biases and weaknesses in a wide range of data
used to analyse the R&D landscape, using emerging biotechnologies as exemplars. We argue
that the types of funding data available are not as representative or comparable as is necessary
for the purposes of tracking technologies. This is a distinct challenge from other perhaps more
easily bounded subject matter such as reporting on academic disciplines, or national activity).
We caution against the assumption that data on R&D funding conforms to the same apparently
more objective characteristics of data studied by scientists within their research fields, and discuss
here why attempts to gather more complete funding data will likely not resolve the problem. In
this way the paper builds on work by NESTA (2006) that discussed the flaws and weaknesses
of singular national statistics, and extends a critique made by one of this paper’s authors in a
recent discussion paper, also on the funding of emerging technologies, for the Nuffield Council
on Bioethics (see Nuffield Council on Bioethics 2012).
On the second question, of alternatives to using R&D funding data, we discuss the utility
of tech mining approaches using proxy measures (Cozzens et al. 2010) for tracking emerging
technologies.
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Just how difficult can it be counting up R&D funding 657
The paper’s theoretically driven critique suggests why proxy measures of technological emer-
gence, despite their drawbacks, will often be insightful for the purposes of tracking technological
options, potentially to a greater extent than more ‘direct’ measures of innovation such as funding
figures.
However, we illustrate proxy measures are diverse in characteristics and no individual measure
will be universally applicable. They must be carefully chosen to be suitable for the fields to
be studied. Strengths and weaknesses of both direct measures of R&D funding and of specific
proxy measures such as patents and publications are explored using a novel taxonomic framework
that builds on conceptualisation of classification issues related to substance and quantification in
Science and Technology Studies (STS), which we set out in Section 2, below. Section 3 discusses
the methods we use to undertake the analysis. Section 4 applies the taxonomy to the problem
of tracking R&D funding in biotechnology, focusing mainly on developed countries. Having
demonstrated the difficulties in collecting R&D funding data on emerging technologies, Section
5 explores some of the benefits and limitations of alternative proxy measures, which are illustrated
in Section 6 through a case study of genomic technology. Section 7 discusses our findings and in
Section 8 we draw our conclusions.
2. Social shaping of substance and quantification in R&D statistics
In this section we describe how an established STS literature on the socially mediated processes
of classifications can be used to provide a helpful framework for understanding a novel problem,
namely establishing investment in emerging technologies and differential investment in distinct
technological options. The challenge here is to understand how collecting and organising infor-
mation turns otherwise formless data into something useful (Headrick 2000). As an illustration of
why this is worth unpacking, even an apparently simple statistical observation such as ‘Germany
spends more on R&D than the European average’ cannot be fully understood without positioning
elements of the statement in at least seven of the ten possible Aristotelian classifications – sub-
stance, quantity, where, when, action, having, relations (Aristotle 1995), making this apparent fact
a highly complex ontological construct.3 Here we focus mainly on the challenges of classifying
substance and quantity, which we suggest raise more particular concerns in relation to the study
of technologies, while the positioning of investments in time and space, for example being more
generic issues, but not necessarily less problematic.
Substance
In referring to substance we mean the type of entity, being, or phenomenon that is to be defined
and classified. This is a most fundamental starting point. Indeed Power (2005, 586) suggests
‘without a system of concepts and taxonomy any practice of intervention is blind, disorganised
and of questionable legitimacy’.
Substances rarely exist in isolation in their natural state and so must be delineated from their
context through the process of definition. Definitions are therefore artificial ontological constructs
that are valid only within certain communities. Definitions are often devised through contentious
processes which may be hidden to those beyond (cognitively, spatially, or temporally) the immedi-
ate debate (Power 2004, 2005). Different communities will have different classifications that suit
their individual needs as parties make formal or informal attempts to arrange their classification
to reflect those issues (Bowker and Star 2000). Thus classification systems may have different
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658 M.M. Hopkins and J. Siepel
scope, and be judged to be too broad or narrow or even irrelevant, by those in other communities.
As a substances are discussed across communities they may become ‘boundary objects’, which:
inhabit several communities of practice and satisfy the informational requirements of each of them.
Boundary objects are thus both plastic enough to adapt to local needs and constraints of the several
parties employing them, yet robust enough to maintain common identity across sites. They are weakly
structured in common use and become strongly structured in individual site use. (Star and Griesemer
1989)
Amid different classification systems, boundary objects provide ideas that link disparate areas of
practice. Yet between different systems those broadly understood terms may be the main links,
with subsidiary classifications unresolved. This process of classification underpins our broad view
of the world, from medicine (Bowker and Star 2000) to economics (Hicks 2011). Once created,
classifications may be used for political purposes such as resource allocation, thus unlike natural
phenomena which have an existence outside of human agency – what Searle (1995) refers to as
‘brute facts’, classifications create ‘institutional facts’ (ibid.) and so classification may be perfor-
mative (Power 2005): in other words, it can bring substances into being. Furthermore politically
popular options will attract re-framing of activities. For example, Calvert (2006) observes how
R&D projects can shift between definitions of ‘basic’ or ‘applied’ research or from one subject to
another according to research funding policy.
It follows from the reasoning above that the definition of emerging technological options – the
Substance (S) we are interested in here, will be problematic because of: (S.1) novelty – they are
new, and therefore may not have been the subject of detailed ontological debate, or the results
of such debate may not yet be diffused. Perhaps they may not be perceived as important enough
to classify/ collect data on; (S.2) plurality – of communities and therefore distinct definitions
(either overlapping or orthogonal) based on differing perspectives of what should be categorised
and how, thus inhibiting comparison. (S.3) boundary objects – where the same substance is
recognised by different communities in similar and distinct ways, promoting misinterpretations
(S.4) indistinctness – technologies are still emerging, fusing or evolving and it may not be clear
how they are distinct from prior substance; (S.5) performativity – technological options may be fed
or starved by classification systems when these are coupled to resource allocation with categories
created to reflect the interests of those with power.
Quantification
Quantification itself is an outcome of classifications: once things are classified they can then
be counted (Power 2004). Within the sciences being able to count things is a highly desirable
outcome – Porter (1992) characterises the desire for quantification as the ‘accounting ideal’ – that
is, for the natural world to be clearly defined as a balance sheet. Yet the process of arriving at a
numerical result is not trivial, but instead heavily contested – given a political tendency for ‘trust
in numbers’ (Porter 1996) the process of making the end result becomes crucial. For instance, the
process of determining what gets counted and what does not is therefore inherently political, and
the determination of the ‘rules’ by which data is collected can have meaningful impacts on the
management decisions taken with the data, as seen in a discussion of the calculation of Canadian
crime statistics (Haggerty 2001).
The following summary draws exclusively on recent studies of performance measures in man-
agement (Power 2004) and financial risk in banking (Power 2005) to provide an extensive (but not
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Just how difficult can it be counting up R&D funding 659
comprehensive) account of why Quantification (Q) of data is often problematic: (Q.1) Method –
the ability to collect and measure data may not exist, even if it is possible to conceive a classi-
fication system (for example, how many black holes are there in the universe?); (Q.2) Quanta –
the unit of measurement must be agreed and data collected in that mode e.g. which currency to
count in, how to relate historical and current prices; (Q.3) Norms – where different methods of
counting may be employed by different agents, for example, what thresholds should be set for
minimum values worth collecting? (Q.4) Jurisdiction – data sources are dispersed such that they
are the property of multiple agents or research participants and subject to access restrictions, or
associated costs, making the output of collection uneven. (Q.5) Incentives – agents or research
subjects may be likely to materially benefit or lose out from under or over reporting of data thus
distorting search results; (Q.6) Judgement – ambiguity over which of two or more classifications
to allocate an instantiation opens the way to subjectivity and potentially bias; (Q.7) Confidentiality
– some data may be unavailable owing to commercial concerns or contractual obligations; (Q8)
Loss – the subject of study may have decayed, or may no longer exist, may be hidden or lost; (Q.9)
Audit – quantification processes may yield to replication, transparency of method, and therefore
establishment of best practice, monitoring and trust, and these may all influence the effectiveness
of data collection undertaken as part of an established routine.
Additional to prior findings reviewed above, we propose two additional factors. First, stemming
from the observation that technologies are not immutable, we might expect (Q.10) transformation
– of substance and/or classification. Change over time means that what begins as funding for one
field may yield results that can be classified in another at a later date. Equally classification
systems will transform as well thus categories will split or fuse. Finally, (Q.11) Cost – it must be
recognised that in many cases data is not valued sufficiently for the costs of collection to be met.
The taxonomised issues above are set out in Table 1 which groups these 16 issues into five wider
categories, two relating to Substance (Definition, Emergence) and three relating to quantification
(Counting processes; Data gathering; Data decay). We now move to explore the extent to which
direct and indirect measures of technological options suffer from these problems.
3. Method
In the following section we demonstrate how the above issues arise in attempts to track R&D
funding in technological options using the case of emerging biotechnologies. The empirical work
is based on review of an illustrative range of the secondary sources where extensive accounts
of activity in biomedical R&D are provided focusing mainly on recent and widely available
work produced the UK, EU and USA. Additional insights were gained from four interviews
with authors of four reports that have attempted to collate R&D funding in the field, based on a
convenience sample. This is sufficient because the primary aim of the above empirical strategy is
purely to illustrate that factors S1–5 and Q1–11 have impinged on attempts to classify substance
and quantity in relation to emerging technologies, and thereby to validate the utility taxonomy
presented in the previous section.
In Section 6 we draw on prior published research to illustrate the strengths and weaknesses of
Tech-Mining using proxy measures in relation to the same factors mentioned above. An example
is provided drawing on prior research by one of the authors, together with colleagues, on the
emergence and use of genomic technology in biomedicine. The methods used for these studies
are referred to in the text where essential to demonstrate key points but due to space limitations
here, full details may be found in the original publications only.
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Table 1. Factors affecting data codification and comparison between R&D funding and patent/publication proxies
Category Facet of codification R&D investment figures Patents Publications
Substance:
Definition
Plurality Different providers of data use
different definitions. R&D
figures generated by diverse
private organisations make
it difficult to account
for specific emerging
technologies; public R&D
figures are missing data
and comparability between
funders is often not possible
where definitions differ
Flexible, classification system
based on key words and
classes (Strumsky et al.
2012)
Flexible classifications
available using author,
institution, keyword etc.
(Rafols et al. 2012)
Indistinctness Difficult to distinguish the
contribution of or to a new
technology when outputs
can be produced using
older technologies
Citations allow the influence
of distinct cognitive
approaches to be mapped,
so long as the technology
is patentable and not
subject to other forms of
appropriation (Hall, Jaffe,
and Trajtenberg 2001)
Citations allow the influence
of distinct cognitive
approaches to be mapped
but data may be incomplete
owing to problems with
matching (Moed 2002)
Boundary objects Lack of a common definition
across boundaries makes
‘biotechnology’ commonly
understood but with
different meanings
Classification systems
make definition explicit
but may not fully
represent characteristics of
technologies (Benner and
Waldfogel 2008)
Classifications make
definition explicit, though
citation process is socially
mediated (Nicholaisen
2008)
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Substance:
Emergence
Novelty Research on discrete new
areas is difficult to observe
as it is not recognised. In
some cases ‘bootlegging’
means work carried
out may not reflect stated
purposes of funding for new
projects in unsanctioned
areas of investigation
(Augsdorfer 1996)
New technologies and
patent categories emerge
following regular reviews
but terminology may
change over time
New journals are created and
categories are altered, but
these may be delayed
Peformativity Tendency for categories to
reflect areas of interest
reflects back on demand for
funding
Many patent citations added
by examiners, introducing
noise (Alcacer and
Gittelman 2006)
Self-citation, enforced citation
and other game-playing
impact on publication
behaviour (Bornmann
2011)
Quantification:
Processes of
counting
Quanta Varies with definition: for
instance ‘biotechnology’,
‘firm’, ‘funder’, etc.
Clearly defined but not
representative of all
innovation: some
innovations not patentable,
others not appropriable
with patents (Hall, Jaffe,
and Trajtenberg 2001)
Clearly defined but not
necessarily equal owing to
uneven definitions, ‘salami
slicing’ and the Matthew
effect (Bornmann 2011)
Method Difficult to identify the full
range of funders and their
influences – tendency to
assume observed research
funding is representative of
the global level, which is
misleading
Large datasets are already
collected with all active
organisations represented
in patent database universes
at least in major markets
such as developed countries
(e.g. patstat, USPTO)
Large datasets are already
collected with many active
organisations globally
– although subject to
language biases; logistical
issues posed by download
limits, citation matching,
etc.
(Continued).
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Table 1. Continued.
Category Facet of codification R&D investment figures Patents Publications
Norms/thresholds Different
countries/organisations
use different definitions
of biotechnology but
also count activities of a
particular scale (e.g. only
dedicated biotech firms or
firms whose major activity
is biotechnology) and
so calculate their figures
differently
Criteria for granting patents
may exclude some
innovations
Threshold for publication in
different journals varies
Judgement Researchers must make
a subjective judgement
about the point at which a
firm may have sufficient
‘biotechnology’ activities
to be considered as a
biotechnology firm. Where
many are involved in this
process, differences in
judgement will make data
less consistent
Researcher is reliant on
indexes, and externally
generated and awarded
classifications; patent
examiners assign many
citations (Tan and Roberts
2010)
Researcher is reliant on
publication indexes, as well
as and externally generated
classifications
Audit Where data is collected
regularly, routines for
consistent can develop. But
different auditing systems
(RePORT, RCUK‘s
gateway) do not guarantee
compatibility of data
between systems
Internal review processes for
patent authorities ensure
validity of work within a
jurisdiction.
Peer review system has its
own biases (Hojat, Gonella,
and Caelleigh 2003), as
do citations and journal
impact rankings (Glanzel
and Moed 2002)
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Quantification:
Data collection
Incentives Respondents not incentivesed
to share data; international
partners potentially not
incentivised to collaborate
Financial incentives
to patenting, where
innovation is patentable
and appropriable
Incentives to publish vary,
with different incentives
for publishing in indexed
journals (Veugelers 2005);
incentives may lead to
over/under-stating private
sector research)
Jurisdiction National funding agencies and
other bodies may restrict
access to data, making
comparison difficult
Different norms for patent
procedures and citations
between US and EU may
make direct comparison
difficult
Non-English publication
language biases may
understate research across
countries
Confidentiality Proprietary data and
commercial confidentiality
make data collection
difficult
Most data public, where
patents exist
Most data available by
subscription, though some
content remains behind
paywalls
Cost Highly intensive of time and
effort
Low cost or free; additional
time required for cleaning
Low cost or free; Generally
limited to appropriate
subscriptions
Quantification:
Data decay
Transformation Purposes of technologies
change over time, meaning
that ex ante and ex post
funding declarations differ
Potentially difficult to track
over time using traditional
bibliographic techniques
Potentially difficult to track
over time using traditional
bibliographic techniques
Loss Perceptions of investments
change over time such
that projects funded
and observed ex ante
are, ex post, not visible
and funding ascribed to
successful projects
Data is quantified and
long-run, but may be ‘lost’
with changes in language
use, keywords and category
changes
Data is quantified and long-
run but may be ‘lost’ with
changes in language use,
keywords, and category
changes
Summary: R&D Investment vs proxy figures.
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664 M.M. Hopkins and J. Siepel
4. The classification of R&D funding in emerging biotechnologies
4.1. Defining the substance for data collection
The taxonomy described in Section 2 presents a number of key challenges to the description and
quantification of the emergence of new technological options. Out of the issues identified there
(summarised in Table 1), we may identify two sets of challenges of identifying the substance of
new and emerging technologies: definition and emergence.
4.1.1. Definition
Even among existing technological categories, there are several issues that make the establishment
of cleanly cut categories fundamentally difficult (OECD 2009). This is even the case for the
OECD, which since Chris Freeman’s initial efforts in the 1960s have published six editions of the
Frascati Manual, dedicated to the accurate collection of international R&D statistics.4 The plurality
and indistinctness inherent in the categories used to classify technologies, and development of
boundary objects common in discussions of innovation, complicate the establishment of reliable
grounds for comparison. Inevitably in describing when these issues arise we will encounter in
passing other related problems to do with quantification (such as judgement) however we will
revisit these later in our account.
In the context of our illustrative analysis on emerging biotechnologies, it is important to high-
light that even the basic definition of key terms such as life sciences industry or biotech firm
are not necessarily agreed, or clear (BIS 2010; OECD 2009). For example the journal Nature
Biotechnology has a long running annual global survey of the stock-market listed biotech firms
but notes ‘as the industry has grown and changed so has our definition of what constitutes a
biotech company and our methods for gathering data’ (Huggett et al. 2011, 585). In part this is
because data gathering complexity has reached the scale that Nature Biotechnology now has to
rely on the international consultancy, Ernst and Young, whose own definition is distinct.
The OECD has also tried to develop a global survey to support a detailed statistical resource
focused on ‘biotechnology’ for which it has established an internationally used definition:
The application of science and technology to living organisms, as well as parts, products and models
thereof, to alter living or non-living materials for the production of knowledge, goods and services.
(OECD 2005)
However the OECD rely on member states to undertake national surveys and these often use
distinct definitions (OECD 2009). Furthermore broad definitions such as the above are open to
judgement during attempts at quantification. For example, application of science and technology
to living organisms, might be interpreted as developing purely mechanical devices (e.g. stents)
and applying these to living organisms. The OECD therefore recommends that single definitions
be accompanied by lists of technical approaches that would fall within the definition (OECD 2009,
9). Thus plurality of definitions disrupts comparability unless carefully considered in co-ordinated
data collection efforts.
When the OECD sought to collect comparable statistics on biotech firm numbers in 26 coun-
tries, surveys and data gathering was undertaken by agents in different jurisdictions, the term
‘biotechnology’ became a boundary object as there different ways to classify the firms as Figure 1
illustrates.Also fundamental is distinguishing between biotechnology and traditional technologies
used in pharmaceutical R&D, one of the largest users of biotechnology: What is the contribution
of biotechnologies, for example tools like gene cloning, to development of pharmaceuticals? The
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Su
sse
x L
ibr
ary
] a
t 0
3:4
2 2
3 J
an
ua
ry
 20
14
 
Just how difficult can it be counting up R&D funding 665
Figure 1. Definitions of the biotechnology industry.
Source: OECD (2009).
indistinctness between categories of ‘biotechnology’ and other health-related R&D makes this
more difficult to measure (OECD 2009, 84).
Definition in private sector R&D. In examining the emergence of new technologies, identifying
the value of private sector spending is crucial as this represents the largest total investment in
biotechnology-related R&D.5 Morgan Jones and Grant (2011) show the total UK public sector
spending on health related R&D was £1.5bn in 2008/2009, while biomedical charities spent
£1.1bn, and private industry invested £8.9bn. Consequently the question of whether it is possible to
identify how different technological options are financially supported therefore primarily becomes
a question of whether it is possible to track the R&D expenditures of a relatively few large
pharmaceutical firms (the top 15 US/EU firms spent US$50 billion in R&D in 2009 – Rafols
et al. 2012). Yet the private sector’s systems for accounting for spending on new technologies is
opaque making it very difficult to identify levels of investment in specific areas.
For example one interviewee suggested that pharmaceutical firms tend to begin accounting for
technologies once they reach clinical trials rather than before and when asked to estimate their
spending by types of market to estimate their spending on orphan drugs he recalled:
they told us it would be difficult to disentangle that information internally, they wouldn’t recognise
what was orphan and non-orphan … they didn’t know how to apportion it internally.
These results do not reflect confidentiality (although this may be relevant too in some cases) but
the interviewee maintained, this was because of the motivation for collecting the data in the first
place as he explained:
if they [big pharma firm X] have a research facility at [town Y] all they need to know is how much
it costs to keep going. Sometimes those facilities coincide with projects in individual groups of
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666 M.M. Hopkins and J. Siepel
technology or individual technologies if you are lucky but most of the time they don’t. They never
actually have the information in the form you need it for the type of [report] you are talking about.
In this context the thorough identification of funding for particular technologies, this becomes
very difficult. To the firm, a proposal to measure investment in a type of technology is entirely
novel as this is not a classification system they use, and the analyst collecting such data has to build
their estimate from scratch as well. Consequently the firm and the researcher are both confronted
with novelty (see also Section 4.1.2).
Definition in public sector R&D. Within the public sector, there is considerable scope for
plurality among the different funders who to categorise investments in their own biomedical
R&D. The definitions used by one organisation’s funding regime may differ considerably from
that of another in the same country or within the organisation over time. Leaving aside the issue
of large differences in the response rates in different countries who were invited to contribute
to research studies (Section 4.2.2 revisits issues such as incentives, and problems of working
across multiple jurisdictions). However even where there was support, classifying information
even into broad sectors of application was difficult: ‘She doesn’t use our categories, we don’t
use hers’ one interviewee concluded looking back at material gathered for their empirical study.
Perhaps it is inevitable that as a result the interviewee recalled ‘Most respondents leave empty the
specifications of percentage allocated to different funding categories by application areas covered
and activities.’ However, the interviewee suggested that funders could distinguish qualitatively
the goals (for example firm creation) and activities their funding aimed to support, for example if
the funding was meant for applied research or basic research.
4.1.2. Substance: emergence
An initial starting point in analysis of a new technology relates to the identification of the new
technology. In this case there are two key issues identified previously, in line with Power (2004,
2005): novelty and performativity. As a new technology emerges, a framework must exist for it
to be worthy of identification as being new. The challenge of capturing novelty is fundamentally
difficult for several reasons. First, there is likely to be a lag between work commencing on a
technology and the new classification system being developed. Second, the new phenomena may
initially be classified as a subset of some existing classification at least until it is given its own
grouping. For example, to find financing via corporate alliances for the emerging technology
of RNA inference using Deloitte’s Recombinant Capital database, in recent years it has been
necessary to look under ‘antisense technology’, a prior technology that has a similar (but distinct)
operational principle. Third, novel activities may be actively hidden and unreported even to those
managing the organisations that support them especially where these are utilising funding that
has not been approved (Augsdorfer 1996).
Novelty is an issue for public sector organisations too. Consider the most accessible dataset on
funding of biomedical research is provided by the US National Institutes of Health (NIH). The
NIH distributes over US$30bn annually in research, mainly to hospitals, universities and its own
laboratories. It is possible to explore the allocation of funding since 2008 using the NIH Research
Portfolio Online Reporting Tools (RePORT). However there are some limitations to the system
and only data on pre-determined categories are provided. The mix of diseases, technologies and
disciplines that form the current set of categories is not comprehensive and is uneven in coverage
(see Figures 2 and 3). The types of technologies that can be searched are shown in Figure 2.
For example while it is possible to find money spent on genetic testing, it is not possible to
search for diagnostics overall. There is no category for pharmaceuticals or sub-types of drugs,
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Figure 2. NIH funding (US$m) in 2011 in selected non-disease specific fields.
Figure 3. NIH funding (US$m) in 2011 NIH in selected disease areas.
such as monoclonal antibodies, although orphan drugs have a category. There are overlapping
categories for regenerative medicine and stem cells, immunization and vaccines, but none for
medical devices.
The analytical typology reflected the NIH in RePORT reflects ‘categories … that were, over
time, requested by Congress and other Federal agencies for reporting to Congress and the public’
(NIH FAQs). The categories available therefore reflect those fields that are of political interest, in
broad terms, and not an analytical technological typology. This reflects the inherent performativity
associated with identification of new technologies; the categories used reflect the political priorities
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668 M.M. Hopkins and J. Siepel
of those funding research, and these interests are then reflected in what is funded. Because Figure 3
shows a small number of relatively non-overlapping disease categories, chosen for illustration only
(but many sub-classes especially of cancer are available) as well as levels of funding support for
areas that cut across diseases including technologies and research approaches (and will therefore
overlap substantially, for example gene therapy would be entirely contained within biotechnology.
The use of categories that reflect political priorities means that other, new technologies will not be
reflected in the given system until they are identified as a new phenomenon worthy of categorisation
by politicians or policymakers – only at which point will the technology be officially observed.
4.2. Quantification
While the previous section highlighted the challenges with identifying clear-cut categories, even if
such categories existed there would be numerous problems with the actual quantification of R&D
investments. This section highlights three thematic problems around quantification – processes
of counting, gathering, and degradation of over time – around which we frame the issues to
quantification identified in Section 2.
4.2.1. Processes of counting
For the quantification of biotechnology R&D funding data, it would be overly simplistic to suggest
that an obvious, objective means of counting exists. Consequently the issue of methodology is
non-trivial over many dimensions. There are questions of quanta – units of analysis – and the
norms of data counting such as at which threshold a phenomenon is deemed to be observed
or worth counting. Also there remains considerable room for judgement by researchers about
what to include and which category to put observations in. For instance, simply identifying the
number of firms or institutions conducting research in a given field can be relatively difficult. As
discussed above, ‘biotechnology firms’represent boundary objects that can include a range of firms
conducting any number of biotechnology-related activities. Because there is no way of knowing
which firms are conducting these activities without asking, there is an instantaneous problem
simply in identifying where to start. Therefore, simply counting biotechnology firms becomes
more difficult, as researchers must make a subjective judgement about the point at which a firm
may have sufficient ‘biotechnology’ activities to be considered as a biotechnology firm.
The private sector is not unique in being difficult to identify actors. The same problem exists
in the public sector, where the sheer number of funders – even in a relatively small country like
the UK – makes finding a method for merely identifying those funding research problematic. For
example, Morgan Jones and Grant (2011) undertook a study for the UK Department of Health to
identify funders supporting the relatively small field of complex trauma, having initially identified
the main funders of UK public-sector R&D. This was achieved by first undertaking interviews with
scientists in the field and then a bibliometric analysis, using key words, to identify publications
in the field to track authors of relevant research and finally find out who had funded this work.
The need to find funding support mechanisms within government departments, at national and
regional levels, as well as charitable and large and small private firms makes this time consuming.
In other instances firms or public sector organisations may be required to respond to surveys to
report activities which may collated in national statistics (Patel 2012).
Table 2 shows that when the OECD (2009) attempted to gather data on public sector investments
in biotechnology from countries, few members responded and in those that did the method was
different in almost all cases as these differed in sample frame, whether responses are mandatory
or non-mandatory and by extent of coverage.
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Just how difficult can it be counting up R&D funding 669
Table 2. List of countries providing data on aggregate R&D spending (all global data available)
Biotech Sample Who conducted
Country Year definition frame used Extent of coverage Mandatory? survey
Canada 2005/6 OECD Census Federal govt departments
and agencies performing
science and technology
(S&T) or with budgetary
allocation to fund S&T
Yes Govt
Czech
Republic
2007 OECD R&D survey All Yes Govt
Korea 2006 All R&D survey All No NIFU STEP
Norway 2005 OECD Census Total higher education
sector and the
Norwegian Institute
sector
No Govt
Poland 2005 OECD Secondary
sources
Selected for S&T Yes Govt
Spain 2006 OECD Census Only government
institutions with S&T
activities or budgets
Yes Govt
Slovenia 2005 OECD Secondary
sources
Selected for S&T Yes Govt
Source: OECD (2009).
Furthermore studies sponsored at a national level may focus on national institutions, but a
national innovation system may benefit from international inputs at multiple points, such as
research grants and multinational corporate R&D (Enzing et al. 2008). However in practice
studies have not tracked international influences as one interviewee noted:
in terms of research outcomes it is actually impossible to take into account international influence …
we all recognise that it is there but I am not aware of anyone taking [it] into account … other than
assuming it away [i.e.] just looking at the US and saying let’s assume the US equals the world because
it is a dominant player in medical research and a very large economy by itself.
These factors combine to make it difficult to establish a clearly auditable trail linking money
actually spent to figures generated for biotechnology R&D. Different organisations may have
their own audit practices whereby the requirement to produce data year after year generates
substantial expertise and will improve the internal consistency of data – for instance as the US
NIH RePOST system is doing. However the range of methods and systems for capturing these
practices makes it very difficult to clearly identify ways of making the data from different systems
sufficiently compatible to be able to draw meaningful conclusions about new technologies across
the jurisdictions of different funders.
4.2.2. Data gathering
For all the problems of counting (even sources of) biomedical R&D identified above, there are
also several more practical problems with the collection of substantial meaningful data. Issues of
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670 M.M. Hopkins and J. Siepel
incentives, jurisdiction, confidentiality and cost also impact the ability of researchers to collect
useful data about R&D spending.
The ultimate aim of any analysis of R&D spending is to draw a meaningful conclusion about
the level of investment in a new technology, but aggregating data from different sources in a form
in which it may be successfully analysed is fundamentally difficult. Beyond the issues discussed
above regarding the establishment of categories and methodologies, there are fundamental issues
of incentives and jurisdiction, which limit the ability to aggregate data without bias. The issue
of incentives is key to data collection – the collection of data is predicated on any particular
agent’s willingness to give correct information. For private sector organisations, even if they
could classify their own R&D spending on emerging technologies (which, as discussed above
they often cannot), incentives to respond to researchers, or even to produce information for other
purposes that researchers can draw on, will vary.
An example of independently produced information that researchers can use would be press
releases or on company websites, but these are subject to reporting biases as a result of varying
incentives depending on ownership types, age, etc. Further, while some organisations (public
sector or private) may be compelled by legal or political reasons to disclose information, others
may be less willing, contributing to an overall response bias that is intractable, as the information
not provided is difficult or impossible to find elsewhere.
Coupled with issues of response bias and incentives is the broad challenge of data gather-
ing owing to jurisdiction and confidentiality (already mentioned above) and cost. There are, as
mentioned in the previous section, considerable issues with substance categorisation and meth-
ods among different countries. Furthermore, accessing data and participants on an international
scale often necessitates work with foreign partners who have access to data. The scope of data
collected is determined by the definition of the field as established by the analyst, but this may
not be reflected in the data collection systems within different countries. Consequently data has
to be discussed and collected through an interactive process with funders – who may or may
not devote their time to helping with such enquiries. Consequently, without the ability to shape
the collection systems and rules for quantification, different figures (such as those in Table 1)
are produced and conflated, making the completeness of ‘aggregate’ figures potentially ques-
tionable and at times outright disputed (for example, see Arundel, van Beuzekom, and Gillespie
2007).
Compounding this problem is the issue of confidential data – for the long-term study of the
emergence of biotechnology there are commercial information providers such as Ernst andYoung,
who have longstanding datasets that have tracked trends in biotechnology, with an annual Beyond
Borders report and contributions to annual reviews by journals such as Nature Biotechnology.
Ernst and Young data is gathered and maintained by what appears to be a large team of analysts,
but is proprietary. While these data may be available to explore for commissioned work such as
business intelligence provision, this comes at a cost.
Obviously, it is important to consider the crucial logistical issue of cost. As valuable as data
on R&D spending may be for a particular area, the costs of collecting or accessing this data
must not outweigh its value. Unfortunately our interviewees highlighted the extensive time costs
of pursuing their own data collection. Morgan Jones and Grant’s (2011) study of the complex
trauma examined a small field (receiving perhaps £15 m per year), but the process of undertaking
interviews with key researchers, bibliometric analysis, funding mechanisms and funding sources
meant that even though funding in only a single financial year was recorded, the exercise out took
several weeks of research. The extension of the project to other areas or countries increases the
complexity many times over; for the report in Enzing et al. (2007) gathering data for public sector
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Just how difficult can it be counting up R&D funding 671
spending on biotechnology took months per country, even for small European countries, and the
reliability of the data was uncertain.
4.2.3. Degradation of data over time
One final issue is that of the dynamics of spending data over time, which relates both the trans-
formation and loss of data. Given scholars’ interest in mapping the long-term trajectories of new
technologies, data extending over a period of time is desirable, thus changes in the nature of
technologies over time are of importance.
When research begins on a new area, its ultimate purpose may not be clear: as our interviewees
commented, spending by pharmaceutical companies on a particular technology is difficult to track
because ‘in preclinical work [pharmaceutical firms’] investment is not technology specific even
if you have access [to interviewees familiar with the technology]’. Further, its utility may in fact
undergo a transformation: ‘you might find something different than you set out to find … look
at anti-retroviral drugs for HIV/AIDS, they were failed cancer drug’. Consequently expenditures
may be recorded differently depending on when an analyst had asked what money was spent on
the first generation of the drug.
Another factor that occurs over time is loss of data, for example, because of recall bias. As time
passes, the memory of projects and their origins can shift, as one interviewee commented:
… there is a difference in the ex-ante and the ex-post view. Ex-post you say this is what we produced
and everything we spent on R&D produced this … . Ex-ante you may think you were spending on a
whole range of stuff most of which never made it to the market.
These difficulties mean that it is important to capture research on emerging technologies as it
happens, as ex-post investigations run the risk of mis-capturing the real expenditures on a range
of new technologies over the extended period of time.
4.3. Summary
This section has described how almost all of the issues anticipated in Section 2 (with the exception
of quanta) have been observed in a review of national and international surveys related to tracking
investments in biotechnology or biomedical sciences. In the following sections we explore whether
proxy measures can provide a way to avoid these difficulties.
5. Proxy measures and tech mining as alternate means of tracking emerging technologies
Having previously focused on the challenges and benefits of tracking R&D spending, now we
similarly explore the properties of proxy measures as means of tracking the evolution of emerging
technologies and related capabilities and research areas. It is important to contrast the definitional
differences between R&D spending and proxy measures; while R&D spending examines inputs
to the innovation process, proxy measures tend to track outputs in various forms. There are a
wide range of outputs of innovative activities that may be used as proxies for tracking innovative
activities – see Patel (2012) for a review. However a suitable proxy for R&D investment should be
close to the act of investment itself and be able to cover the scope of activities that investments may
support (ibid.). Consequently, in the field of emerging biotechnologies, publications and patents
address this area well as these are early outputs in the innovation process: they cover products or
processes (both incremental and major), and they can be collated for a wide range of analytical
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672 M.M. Hopkins and J. Siepel
levels (country, industry, technical field, organisation). Patents and publications can reveal data
on small and large organisations and data is collected internationally and independently (ibid.).
The past 20 years have seen considerable advances in the use of publications and patents as
tools for academic inquiry into science. Bibliometric techniques based on publications, while
originally used as means of measuring scientific excellence, have also been used increasingly to
proxy innovative activities and examine the emergence and evolution of technologies (Veugelers
2005). Given that publications are more likely to come from academic sources (Murray 2002),
publications and citation patterns can be particularly useful for measuring dynamics of scientific
research (Leydesdorff 1987; Boyack, Klavans, and Borner 2005; Porter andYoutie 2009).With this
said, some industries – particularly pharmaceuticals – rely on publications for external validation
of technology (Rafols et al. 2012). Similarly, patents identify in detail the state of a particular
technology, at a particular point in time (Jaffe and Trajtenberg 2002). Because of their requirement
to demonstrate novelty, patents have been widely used as a reflection of organisational R&D
capabilities (Rosenberg 1982; Pavitt 1985;Archibuigi 1992; Jaffe et al. 1993; Jaffe and Trajtenberg
2002). In this section we will examine patents and publications utility for tracing investment
in emerging biotechnologies using the framework discussed in Section 2. We consider these
proxy measures in terms of ‘traditional’ bibliometric methods and also discuss how tech mining
techniques may help to mitigate weaknesses of these techniques. We suggest that while proxy
measures have potential to overcome some of the weaknesses inherent in funding data, they come
with their own biases and logistical issues that must be considered. We then propose that tech
mining may be a useful means to address some of these problems.
5.1. Substance
5.1.1. Substance: definitions
Given the critiques of R&D funding listed above, both patents and publications appear highly
appealing as means for tracking emergence of technologies. Both utilise clearly defined multi-
level indexing categorisation systems whose high-granularly and uniformity make them useful for
analysis. Patents are granted and indexed using standardised codes to identify technologies and
the relative position of a technology by professional patent examiners with expertise in the area
in question. Publications are organised around journal articles, which focus on specific focused
areas and are edited, reviewed and indexed by experts.
Consequently these classification systems may help to address the issues of plurality, indis-
tinctness and boundary objects by operating within specifically identified categories, for instance
patent codes or journals. These categories may serve as units of analysis themselves, for instance
patent codes (Hall, Jaffe, and Trajtenberg 2001; Strumsky et al. 2012) and journals (see Glanzel
and Moed 2002). The parallel issues of indistinctness of new technologies and boundary objects
around unclearly defined topics are addressed by two key factors prevalent in both patents and
publications. In addition to the detailed categories for the classification of new patents or publi-
cations (see uses of these for example in Strumsky et al. 2012; Rafols et al. 2012; Leydesdorff
et al. 2012), both patent and publications acquire citations, which document how a unit of output
relates to previous work. In this way new technologies may be observed from the bottom-up as new
technologies may be traced from the previous advances they cite. In theory such search methods
can generate more sophisticated and granular results than R&D funding data. For example, while
the term ‘biotechnology’ is used in a loose way that serves as a boundary object and leaves the
analyst reliant on funder’s definitions of technology, when using proxies it is possible to identify
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Just how difficult can it be counting up R&D funding 673
all papers or patents citing a specific biotechnology technique or classified in a particular field by
indexers that are independent of the funder.
However while the premise of categorisation and citations for publications and patents may
appear simple, these categories include a range of opaque, socially mediated factors that are
not immediately observable and introduce important biases into our ability to track emerging
technologies. For instance, Benner and Waldfogel (2008) find that using only the first listed
technology code on patents to characterise a patent may mis-state the proximity of technologies,
and publications databases such as ISI rely upon human judgement about content to categorise
journals (Boyack, Klavans, and Borner 2005). Meanwhile the use of citations also has logistical
issues: patent citations come from both the applicant and the examiner, obscuring efforts to
examine the impact or awareness of prior innovations (Alcacer and Gittelman 2006) and for
publications mis-matching of citations is rife (estimated by Moed (2002) to include up to 30%
of citations in some cases), introducing a slightly different element of indistinctness to the issues
discussed for R&D statistics. In addition, it has been argued that citations themselves may be
interpreted as a boundary object, making the rigorous unit of citations less concrete than they
might initially appear.
5.1.2. Substance: emerging technologies
Access to citations also means that the identification of novelty of new technologies is considerably
easier. The bottom-up nature of patents and publication citations means that new technologies
may be tracked from their origins, via the originating papers or patents. Importantly, mechanisms
exist for new categories to come into being: patent offices review and add to coding systems over
time, while new journals may be created to reflect academic advances, and clear procedures exist
for journals to be added to the main databases.6
Again however, there are logistical issues that cloud the effectiveness of these techniques;
delays in the review and publication of results can introduce time lags for the measurement of
new technologies. Similarly there are lags for the review and introduction of new journals. Larsen
and von Ins (2010) suggests a decline in the total amount of scientific activity captured in the
major journal indexes. This may take the form both of new journals, as well as other activities
in the form of working papers, conference papers or other communications outside the realm
of indices (Veugelers 2005). From the perspective of tracking new technologies, this means that
outputs only appear once they have been sufficiently advanced to become outputs; the lag between
input measures such as funding and these outputs are therefore potentially troublesome.
Performativity is an issue as well for publications, which are particularly susceptible to
game-playing activities such as self-citation, coercive citation and pressures in journal selec-
tion. Research may be self-declared to fit into categories that are advantageous for authors to be
classified in (see Calvert 2006).
5.2. Quantification
5.2.1. Quantification: method
The process of quantifying investment in new technologies was discussed earlier as being fraught
with difficulties for the study of biotechnology R&D. This process is, superficially, consider-
ably easier for proxy measures. First, the quanta or unit of analysis, is clear: a publication or
patent is the basis of any counting. The method for collection and analysis of data is similarly
straightforward, as databases of patents and publications are available easily and cheaply, and
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Su
sse
x L
ibr
ary
] a
t 0
3:4
2 2
3 J
an
ua
ry
 20
14
 
674 M.M. Hopkins and J. Siepel
maintained by dedicated professionals over long periods of time for primary purposes other than
monitoring technological investments (which provides some neutrality with regards incentives).
It is possible to download thousands of citations for immediate advanced analysis, for which there
is extensive documentation of research methodology in the literature. The norms for inclusion are
clearly recognised standards: for patents the thresholds of novelty, inventiveness and disclosure,
are clearly defined and codified in legislation and case law. For publications the established peer
review system determines which is published, and clear guidelines exist regarding which journals
are included in major databases (see ThomsonReuters 2012). Once a researcher is conducting
analysis on either patents or publications, many questions of judgement may have been made by
professional examiners or indexers. Finally, the use of patents and publications to track technolo-
gies feeds upon inherently auditable mechanisms required to make both systems robust to legal
or academic scrutiny.
Again, however, there are theoretical and practical issues posed by these proxy measures. In
terms of threshold and quanta, not all innovations are patentable, and of those that are patentable
not all reach the threshold to be granted (Hall, Jaffe, and Trajtenberg 2001). Even those meeting
patentability criteria may not be granted for economic reasons. Similarly the political processes
inherent in the peer review system means thresholds for acceptance to journals are uneven (Hojat,
Gonnella, and Caelleigh 2003). The judgement by the analyst is replaced by the (still subjective)
judgements of patent examiners and indexers involved in classification of journal articles, meaning
researchers have less control over the terms used in quantifying these innovative activities. In
addition to all of these, the methods required to track emerging technologies in patent or publication
databases are made more difficult by challenges in cleaning, matching and preparing data that
may not have originally been intended for this type of analysis.
5.2.2. Quantification: data gathering
The mechanics of drawing conclusions from proxy measures represents both benefits and draw-
backs. The advantages are significant: the cost of accessing patent and publication data is relatively
low, both for the subscription to the databases (at least assuming academic analysts) and for
software required for analysis. Incentives to participate are also addressed by the design of the
patent/publication systems – the observation of innovative activity using patents or publications
is a secondary consequence of individuals and firms’desire to protect and/or publicise their work.
These rewards encourage the disclosure of information that would otherwise be kept secret. This
means that confidentiality is less of an issue for proxies than for R&D figures, as one key element
of patenting or publication is the disclosure of information in return for rewards. Of course the
public nature of these disclosures does mean that some innovations will not be captured, either
because they cannot be patented, because of commercial sensitivities about appropriation, or
because of security concerns (i.e. ‘black patents’); however for these it is not clear that data on
R&D investment would be any more illuminating.
There are other issues associated with collecting of data. Incentives to publish – particularly
for private firms – are not necessarily driven by a straightforward desire to engage with academic
debate (Sismondo 2009). Consequently the publication activities of firms may at various points
overstate (Hicks 1995) or understate (Sismondo 2007) the actual level of research taking place.
Perhaps a greater concern for both patents and publications comes from the issue of international
data gathering, which presents a different facet of the issue of jurisdiction. Propensity to patent is
not consistent across countries (especially developing countries) or industries, e.g. software, ser-
vices (Archibuigi and Pianta 1996). Moreover, patents represent the result of a process externally
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Just how difficult can it be counting up R&D funding 675
mediated by patent examiners, and reflect national contexts, which result in different citation pat-
terns (Meyer 2000; Alcacer, Gittelman, and Sampat 2009), while the costs in obtaining granted
patents may mean smaller organisations or academic organisations are less active (Hopkins et al.
2006). For similar reasons we can expect those from developing countries will be less able to afford
large patent portfolios. Consequently, conclusions about cross-national activities require caution
as the rules and citation patterns nationally may be fundamentally different. A similar issue exists
for publications, where non English-speaking countries may have non-English publications that
are not captured or are undercounted in mainstream databases and may reflect different citation
patterns, which may then impact on other research (see Van Leeuwen et al. 2001). In addition
to these issues, there are more basic logistical issues posed by work with proxies; while costs
of access are relatively low, there are challenges posed by limits to downloads, restrictions on
database access (especially to non-academic analysts) and other matters that can significantly
impede a researcher’s progress.
5.2.3. Quantification: decay of data
The issue of the loss of data with memory is effectively avoided with the use of proxy measures
such as patents and publications in the digital age because patent and publication data now exist
in accessible forms covering long periods of time, it is possible to track the long-run evolution
of capabilities over time (see Jaffe et al. 1993; Gittelman and Kogut 2003; Hess and Rothaermel
2011). The transformation of technologies may, in these circumstances, be observed and stud-
ied rather than be the source of uncertainty about the counting of bits of data. With this said,
transformation may only be possible to observe in cases where the keywords and terms for tech-
nologies remain constant over time; in these cases there is potential for data to be lost if traditional
bibliometric techniques (using titles, authors, keywords, etc.) are used.
5.3. The prospect of tech mining for improving publication and patent analysis
Our previous discussion has mostly focused on the uses of proxy measures and the implicit use
of traditional techniques to analyse them. However it is important to emphasise the potential held
by new tech mining techniques based on analysis of co-occurrence of proximate terms within text
to improve the ability to generate insights from these proxy measures. Tech mining approaches
show considerable potential to build on advantageous characteristics of proxy data – for instance
large and low-cost datasets that are indexed independently of funders, but to mitigate some issues
identified above. For instance, tech mining techniques may be used to identify larger and more
precise datasets related to novel technologies, perhaps from an earlier stage than might otherwise
be observed using publications indexed in the traditional manner, and data mining techniques
have potential to aid in the observation of transformation of technologies over time (Yang et al.
2008). Use of tech mining to find semantically related research allows for the mapping of the
emergence of technology in a more sophisticated way than had been done before (see Pudovkin
and Garfield 2002; Morillo, Bordons, and Gomèz 2003).
5.4. Summary
Against the criteria that we identified in Section 2, it is clear that many of the problems that made
use of biotechnology R&D figures troublesome are at least partially resolved by the use of proxies
for tracking technologies, although these measures are far from perfect. Patents and publications,
despite their limitations, are considerably more adaptable and suited to objective quantification
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676 M.M. Hopkins and J. Siepel
than are politically charged figures for funding, and all the attendant problems associated with
them. With their weaknesses these proxies are ultimately complementary, and can be used together
to offset weaknesses and to provide the possibility of multiple partial indicators which, when giving
convergent results, provide a stronger signal for policy and strategy deliberations (Martin 1996).
6. Combined funding measures and proxies in action – the emergence of genomics
as a drug discovery technology
To support the claims of the previous section, here we present an example of the different conclu-
sions that may be drawn from input–output and proxy measures of biomedical R&D. Around the
time of the Human Genome Project (1990–2003) and for some years afterwards, high expectations
surrounded techniques that allowed the sequencing of genes, and analysis of their structure and
roles in relation to the biological processes linked with disease. These genomic technologies were
seen as crucial new tools for drug discovery efforts across the pharmaceutical industry that would
allow identification of the root causes of pathologies and facilitate the design of more precise
molecular interventions (Martin et al. 2009).
During the 1990s scores of dedicated biotechnology firms were founded specifically to exploit
genomics, first using technology platforms to identify potential disease mechanisms, and later
through development of their own drugs based on genomic insights (Rothman and Kraft 2006).
In 1999 as firms and public organisations raced to sequence the human genome and technology
financing was in a boom phase, the New York Times interviewed William Haseltine, the CEO of
one leading genomics firm, Human Genome Sciences, who provocatively stated: ‘Any company
that wants to be in the business of using genes, proteins or antibodies as drugs has a very high
probability of running afoul of our patents …. From a commercial point of view, they are severely
constrained – and far more than they realize’.7
In light of the apparent progress of the genomics firms, the stakes seemed extremely high as a
new sub-sector of the pharmaceutical industry emerged. By 2000, the top 5 genomics firms were
valued at US$45bn on US stock markets (collectively equivalent to the size of a top pharmaceutical
firm). It was (and remains) relatively straightforward to assess the progress of these would-
be challengers to the incumbent pharmaceutical firms, given the main focus of these firms is
exploiting genomics and the resulting products and revenues stem from investments in this field.
Such measures as R&D investment, progress of products through the drug development pipeline
(including historical views) are shown in Table 3 for leading genomics firms, as collected from
Securities and Exchange Commission filings.
By contrast when looking for comparable data from pharmaceutical firms, we find only firm-
level data on R&D spending as a whole. It is not possible from an external vantage, or even perhaps
internally, to use the same measures to tell which of the many products under development are the
result of investments in genomics (which can support the discovery of different modes of therapy)
or how much of total R&D spending is devoted to this activity. However annual reports, press
releases and corporate alliances all gave signals large pharmaceutical firms were active in the field.
Commentators suggested estimates of annual spending of US$100–300 m based on discussions
with firms (Gassmann, Reepmeyer, and von Zedtwitz 2004), although it should now be clear from
the discussion in Section 2 these estimates will be subject to many uncertainties.
It is here that proxy measures provide an opportunity to draw direct comparisons with some
precision and to ask the question, to what extent are pharmaceutical firms keeping up with new
entrants in the field of genomics?
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Table 3. Measures of progress in leading genomics firms
Revenue Revenue R&D R&D No. of molecules Lead
(US$m) (US$m) (US$m) (US$m) in pipeline compound
Company name 2004 2008 2004 2008 (2010) stage (2010)
Human Genome
Sciences
3.8 48.4 219.6 242.7 8 Market
Rigel 4.7 109.7 48.5 8.0 8 Phase 2
Sangamo
Biosciences
1.3 16.2 11.1 31.2 1 Phase 2
Maxygen 16.3 100.7 53.3 46.3 3 Phase 2
Ariad 7.4 8.75 27.7 50.8 3 Phase 3
Incyte 14.2 3.9 88.3 87.6 12 Phase 3
Lexicon
Pharmaceuticals
61.7 32.3 90.6 108.6 5 Phase 2
Exelixis 52.9 117.9 137.8 257.3 14 Phase 3
Arena 13.7 9.8 57.7 204.4 5 At FDA approval
Source: SEC filings.
6.1. Patents as proxies
Patents claiming DNA sequences can be selected directly from patent databases such as patent
lens or specialist indexers such as Thomson Scientific, without the need to search specific
patent classes (see method for collection in Hopkins et al. 2006). These are used here as an
appropriate a proxy for investment in genomics as these are gained only for novel inventions
(a sign of capability) and novel DNA sequences are only accessible using genetic techniques
(or else indirectly deduced using slower but closely related protein sequencing approaches)
and so these are reasonably specific proxies. The costs of writing and obtaining a US patent
in biotechnology are relatively inexpensive, perhaps US$10,000 compared with Ł55,000 for a
granted patent at the European Patent Office (Hopkins et al. 2007) thus few firms should be
excluded from visibility by using this measure. Furthermore all firms engaged in genomics
had, at the time, a strong incentive to patent as access to future drug targets was felt to
be at stake (although Hopkins et al. (2007) note the intellectual property regime around this
particular field has weakened since 2001 and such changes are an important contextual ele-
ment to be considered in selection of proxies). Patents claiming DNA sequences are selected
as suitable proxy-measure in this instance because these are found to be routinely generated
as a product of research by many firms, in an industry with a high propensity to patent.
Furthermore, US patent grants are selected as the USA is the world’s largest market for ther-
apeutics thus firms looking to exploit genomics for therapeutic purposes could be expected to
focus attention here – indeed most genomics firms were founded in the USA (Martin et al.
2009).
Table 4 distinguishes between dedicated genomics firms and other (pre-genomics) biotech firms,
as well as incumbent pharmaceutical firms (noting any prominent acquisitions of genomic-capable
firms whose patent estate is counted towards the acquirer’s total). The findings are revealing,
showing that (despite Haseltine’s claims) there are more pharmaceutical firms in the top 10
holders of DNA sequence patents than genomics firms, and indeed these firms and others such as
biotech firms e.g. Amgen had been active in the field before the genomics firms were established.
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Table 4. Top 10 corporate holders of DNA patents granted in the USA
US Patents granted (by application period)
All years 1980–1990 1991–1995 1996–2000 2001–2003
Incyte Corp (genomics firm) USA 572 3 22 529 18
AMGEN INC (biotech firm) USA 290 28 85 149 28
Human Genome Sciences (genomics
firm) USA
289 0 83 167 39
Millennium Pharm Inc. (genomics
firm) USA
260 0 19 196 45
GlaxoSmithKline (pharmaceutical
firm) UK
228 2 13 200 13
Isis Pharm Inc. (biotech firm) USA 227 0 6 176 45
Roche (inc. Genentech)
(pharmaceutical/diagnostics
firm) Switzerland
222 21 66 111 24
Applera Corp. (includes Celera)
(instrumentation/genomics) USA
162 0 3 37 122
Wyeth (pharmaceutical firm) USA 153 18 43 83 9
Novartis (inc. Chiron)
(pharmaceutical firm) Switzerland
142 16 57 64 5
Source: Hopkins et al. (2006), 24.
6.2. Scientific publications as a proxy measure
Publications provide an alternative but complementary window on large pharmaceutical firms’
activities in genomics. Large pharmaceutical firms typically publish ca 1000 papers annually each
thus providing an opportunity for analysis of broad-based trends (Rafols et al. 2012). Bibliometric
approaches that use keyword searches can provide high-granularity to distinguish firms as shown
in the example below. The method employed in the Tables 5 and 6 (previously in Hopkins et al.
(2007) – a fuller description is given there) uses search terms that describe genomics-related
techniques that are derived from review of contemporary scientific papers and counting only
research papers (i.e. excluding review articles, editorials, etc.) to ensure that search results indicate
technical activity, rather than simply reflection pieces. Tables 5 and 6 show publications for each
firm by year, shaded in grey where the firm is active (1+ publications per year) darker shades
reflecting higher activity (the darkest being >20 publications per year). Unshaded years indicate
external activity (the field existed but the pharmaceutical firm did not publish), with a ‘0’indicating
discontinuous publishing, while an ‘X’ indicates the field had not emerged at that time and so
publication was not yet possible.
While patents are often necessary to commercially exploit scientific developments in drug dis-
covery, publications may not be, and so propensity to publish scientific papers between firms
varies considerably. For example data from Rafols et al. (2012) shows AstraZeneca and GSK,
the two largest UK pharmaceutical firms, and both in the global top 5 by sales, spent an aver-
age of £2.7bn and £3.1bn respectively on R&D over 2004–2007, but although GSK spent only
15% more it published 33% more papers (AZ published 3282 vs GSK’s 4355 papers). Despite
apparent differences in propensity to publish in general, Tables 5 and 6 show that GSK published
1487 papers within the defined keyword set, compared to AstraZeneca’s 331. This is consistent
with the patenting position, where AstraZeneca despite being in the top 10 R&D spenders in
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Table 5. Accumulation of research interests related to genomics at GSK 1991–2003
Subject 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Recombinant DNA 3 1 4 2 2 1 1 0 11 8 3 2 1
Sequencing DNA 7 12 9 15 13 25 20 21 14 41 12 13 15
Gene cloning 18 18 16 15 17 18 14 11 16 25 9 9 5
Protein sequence 20 21 20 27 27 42 29 38 28 39 11 25 20
Protein expression 1 3 3 2 2 3 6 10 6 10 2 11 9
Gene expression 8 6 6 11 17 9 25 30 26 28 21 26 21
Sequence homologies 6 1 4 2 0 4 5 5 7 6 0 7 4
Transgenic animals 1 1 2 1 5 5 6 5 7 4 2 2
DNA database 3 5 5 5 6 8 7 12 6 7 5 3 1
Bioinformatics 1 0 2 3 4 4 11 12 10 9
Gene function 1 1 3 1 5 2 7 3 1
Genome mapping 1 0 1 1 2 4 2 2 1
Gene knockout X 1 0 1 2 1 2 1 1 0
Genotyping 2 2 0 2 5 1 2 4
Population genetics 1 1 1 1 5 0 5 0
Pharmacogenetics 1 0 1 1 7 2 6 2
Microarray 1 0 1 7 4 7 7
Proteomics X X X X X X 1 2 9 6 6 6
SNP analysis X X X 1 4 2 4 2
RNAi X X X X X X X 1 0
Table 6. Accumulation of research interests related genomics at AstraZeneca 1991–2003
Subject 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Recombinant DNA 1 0 0 0 0 0 1 0 0 1 0
Sequencing DNA 7 10 3 2 3 4 2 5 5 2 1 2 2
Gene cloning 5 8 3 7 1 5 0 8 1 4 2 2 1
Protein sequence 3 9 4 4 6 4 3 5 4 5 5 5 8
Protein expression 0 2 0 0 1 0 0 0 2 0 2 2 8
Gene expression 2 7 1 3 3 4 4 8 6 7 2 3 4
Sequence homologies 1 1 0 2 0 0 1 2 0 1 1 0 0
Transgenic animals 0 2 1 4 3 1 1 3 0 2 2 2 0
DNA database 1 2 0 1 0 1 0 1 0 0 0 0 1
Bioinformatics 1 2 2 4
Gene function 2 0 0 0 1 0 1 0 0 1 0 1 0
Genome mapping 1 2 0 0 0 0 0 0 1 0 0 1 0
Gene knockout X 1 0 0 0 0
Genotyping 1 0 0 0 0 0 2 2 0 1 0 2 0
Population genetics 0 0 0 0 1 1 0 0 0 1 0 1 1
Pharmacogenetics 1 2 2 0
Microarray 1 0 2 1 2 3
Proteomics X X X X X X 2 3 3 4
SNP analysis X X X
RNAi X X X X X X X
pharmaceuticals (see Rafols et al. 2012) is outside the top 10 holders of DNA patents. Therefore
publication levels suggest that GSK was undertaking much higher levels of research in fields
related to genomics than AZ. This position is further supported by the finding (reported in Martin
et al. 2009) that AZ had only half the commercial alliances in the field compared to GSK, based
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on firm-firm deals announced in the press over the decade 1993–2003.
The contrast between the level of detail presented in input (funding) vs output (proxies) is
considerable. We are able to gain much richer and more detailed information about the actual
research activities of the firms in question using the proxy figures in contrast to the figures for
funding which are only available as estimates by internal company staff.
7. Discussion
This paper has presented and tested a taxonomic framework for examining the strengths and
weaknesses of several methods for tracking R&D activity related to the emergence of technolo-
gies. Using this framework we explore primary and secondary accounts of data collection efforts
revealing at least 16 distinct issues that present problems when attempting to follow which organi-
sations are investing in different forms of technology and the extent to which they are participating
in such activites. This is particularly difficult when we consider that technologies may develop on
a global stage and so the search for their supporters must also be global, and the support of many
different groups may be necessary to collect standardised data. This is likely to be very resource
intensive, and unlikely to be financially viable without the highest levels of political support.
The collection of data from the illustrative field of biotechnology R&D has revealed difficulty
in codifying distinctions between fields of technologies, inability to reflect new and emerging
technologies, considerable methodological differences between different institutions and coun-
tries in the collection and aggregation of data and the decay of data over time. While there is a
demand to have good data on public and private sector investment in new technologies, R&D
financing data gathered for policymaking are often problematic, partitial, or contested (House of
Lords 2010; Anon 2010; Arundel, van Beuzekom, and Gillespie 2007).
The challenges of collecting ‘input’ data for innovation (in the form of R&D spending) may be
contrasted with the use of proxy, ‘output’ measures of innovation. Proxies do not directly capture
funding but represent important intermediate outputs of innovation processes (Patel 2012). We
discuss how centrally gathered and indexed data, based on submissions by organisations for
purposes other than being monitored, can be analysed in diverse ways for up to date or historical
studies. In addition, these measures have other benefits as well: patent and publication databases
are widely available at relatively low cost, and the data on these are carefully indexed over long
periods of time (although there are differences over time in organisational activity and coverage
that require adjustment). Proxies can also be retrospectively interrogated using different keywords
or classifications and without being subject to the sorts of recall bias individuals and organisations
suffer from.
While proxy measures have considerable power to document the evolution of technologies, in
more detail, with greater scope, less direct reliance on the organisations being observed and at
lower cost than similar examinations using R&D data, they also have important drawbacks. The
externally validated categories used for proxy measures reflect human judgement and failure to
account for this may result in misleading understandings of technologies (Benner and Waldfogel
2008). In addition, particularly for publications the key metrics of citations backward and for-
ward may be subject to considerable technical and game-playing problems (Moed 2002; Aksnes
2003). When applied against our framework we find that both patents and publications present
considerably more detail about R&D activities related to emerging technologies than do funding
statistics. Our discussion of the genomics sector in Section 6 demonstrates the extent to which
funding figures neglect the nuances of innovative activity or even fails to find it entirely.
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Additionally, we point to the emergence of tech mining as a tool for analysis of new technologies
as an exciting new frontier for the use of information technology, but a prerequisite for advanced
analysis is suitable data. We suggest that tech mining techniques may allow researchers to mitigate
some of the logistical weaknesses inherent in proxy data by more extensive and sophisticated
textual analysis and searching allowing the evolution of ideas and technologies to be studied
more easily and at scale.
The intent of this framework and discussion is not intended to suggest that R&D funding statis-
tics have no use or that bibliometric and tech mining techniques are unequivocally superior. Both
input and output measures have a role to play in policy discussions and strategic planning, and both
may be used together in a complementary fashion in well-resourced dedicated initiatives. However
we would suggest that the framework introduced in this paper provides a tool for analysing and
understanding the relative strengths and weaknesses of methods of observing emerging technolo-
gies. The example of biotechnology R&D discussed here is a particular instance where conflicting
categories and difficulties in tracking funding make systematic analysis of inputs to innovation
difficult.
An important point on the use of proxies is that the availability of robust datasets relatively
free from manipulation by R&D active organisations themselves, varies greatly by technological
field and industrial sector. Whereas in the analysis of biotechnology, we benefit from a wide
range of proxies as discussed in this paper, analysis of other sectors using advanced techniques
may require alternate measures of innovative activity (such as inter alia, new products launched
or commercial alliances.). The framework we have elucidated here provides to researchers and
policymakers a straightforward tool for making judgements about the validity of proxies for active
involvement in emerging technological fields. While no single measure is likely to capture the
complex picture of activity stemming from investments in emerging technologies, this framework
allows the assessment of different measures of such activity, facilitating the relative judgement of
suitability and potentially influencing modes of data collection and analysis.
There are a number of areas in which this framework can be applied. This paper as focused on the
emergence of biotechnologies, but other technological areas may be addressed. Another potential
application would be in the evaluation of measures of innovation in developed and emerging
economies. Historically the measurement of capability development in developing countries has
been plagued with methodological problems (see Archibuigi and Coco 2004), as some proxy
measures of innovation such as patenting and publications are difficult to measure widely outside
of the institutions in the developed countries.While we cannot provide a one-size-fits-all solution to
this significant problem, our framework provides a meaningful tool for the evaluation of different
measures of innovation in these circumstances. The institutional challenges that policymakers
face in these circumstances (for instance data sharing) are reflected in our framework, and as
such the framework allows comparisons of the effectiveness of a range of measures in capturing
innovative activity.
8. Conclusions
Emerging technologies promise much for firms and economies, but the data necessary to track
these technologies in order to make well informed policy and strategy are often not available.
Where data gathering is undertaken, the purpose determines who collects the data, and who
contributes, how much care they take, the form in which data is sought, where it is found, how it
is counted or excluded, aggregated or partitioned, unitised, coded, tabulated, stored, analysed and
presented. Each step further separates the ultimate reader from the phenomena being observed –
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which change as a result of being observed – particularly where funding is involved. Consequently
this begs the question of whether it is indeed possible to truly identify a representative picture of
investments in a given emergent technology, and even if so, whether it is a good use of researchers’
time and effort or the funder’s scare resources.
This paper helps to address this question by presenting a framework for examining the strengths
and weaknesses of different ways of tracking organisations’ activity around emerging technolo-
gies. This framework shows that the challenges of systematically identifying all potential funding
sources for emerging technologies are fundamentally fraught with difficulties with at least 16 bar-
riers to the collection and analysis of comprehensive funding data. We use illustrative data from
biotechnology R&D to argue that proxy measures such as patents or publications can potentially
provide more detailed measures of innovation activity in some cases. Finally we suggest that while
gathering financial data will remain difficult in most circumstances, tech mining approaches have
the potential to mitigate some problems inherent in proxy-based approaches and offer further
promise of improvements in the future.
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Notes
1. Recent schemes include those in the UK by UKCRC, Researchfish Ltd and Research Councils UK research outcomes
tracking system, as well as the NIH’s RePORT in the USA.
2. See House of Commons Science and Technology Committee’s 2010 Report on ‘Setting priorities for pub-
licly funded research Setting priorities for publicly funded research’, chap. 3, paras 25–29. Available at
http://www.publications.parliament.uk/pa/ld200910/ldselect/ldsctech/104/10406.htm (accessed 15 March 2013).
3. This classical taxonomy of classifications is suggested to be a simplification and cannot be regarded as entirely
unproblematic (see Lakoff 1987).
4. http://www.oecd-ilibrary.org/science-and-technology/frascati-manual-2002_9789264199040-en.
5. Levels of private investment are very difficult to access from public reports: In OECD (2009) 24 countries provided data
on numbers of biotechnology firms in their national sectors, but only 13 provided data on the industrial applications
(e.g. health, agriculture, food and beverages) their firms focused on. This is sufficient to account for the sectoral focus
of only 11% of expenditure in the 19 countries providing data on private R&D investments. Consequently it is very
difficult to draw meaningful conclusions from these results, given that they are incomplete in terms both of nations
providing data and the quality of national provided.
6. See for instance the policy for selection to the ISI journal database at free/essays/journal_selection_process/.
http://thomsonreuters.com/products_services/science/free/essays/journal_selection_process/.
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